Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?

about

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.

P2860

Q40039995-5D189D1B-554A-4532-96B7-154D744318DF Q47810732-6CEF13EB-65CC-4AC9-9425-B8B7DF2C0465

P2860

Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?

Item

http://www.wikidata.org/entity/Q39080554

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@en

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@nl

type

Item

label

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@en

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@nl

prefLabel

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@en

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@nl

P1476

Role of Gag mutations in PI re ...... y: bystanders or contributors?

@en

P2093

D Struck

http://www.w3.org/2001/XMLSchema#string

F Schöni-Affolter

http://www.w3.org/2001/XMLSchema#string

J Böni

http://www.w3.org/2001/XMLSchema#string

J Verheyen

http://www.w3.org/2001/XMLSchema#string

K Kletenkov

http://www.w3.org/2001/XMLSchema#string

S Yerly

http://www.w3.org/2001/XMLSchema#string

T Klimkait

http://www.w3.org/2001/XMLSchema#string

V Aubert

http://www.w3.org/2001/XMLSchema#string

P2860

Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study

Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients

Human immunodeficiency virus reverse transcriptase and protease sequence database

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

P304

866-875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKW493

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Swiss HIV Cohort Study

Daniel Hoffmann

P577

2016-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27999036

http://www.w3.org/2001/XMLSchema#string

Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?

about

P2860

P2860

Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698